Filter-Free Retrograde Popliteal JETSTREAM Atherectomy Followed by Drug-Coated Balloon Angioplasty: Procedural Safety and One-Year Clinical and Hemodynamic Outcomes
Journal of Cardiovascular Development and Disease · 2026-11-06 · 13 (11) · 570
DOI: 10.3390/jcdd13110570 ↗Abstract
Background: Endovascular revascularization is an established treatment for symptomatic femoropopliteal peripheral artery disease. Drug-coated balloon angioplasty allows antiproliferative drug delivery without permanent metallic implantation, while atherectomy may facilitate lesion preparation in calcified and occlusive disease. This study evaluated the procedural safety and one-year clinical and hemodynamic outcomes of filter-free retrograde popliteal JETSTREAM atherectomy followed by drug-coated balloon angioplasty, with additional assessment of dual antiplatelet therapy adherence and continued smoking. Methods: This retrospective single-center study evaluated 128 patients treated with filter-free retrograde popliteal JETSTREAM atherectomy followed by Ranger drug-coated balloon angioplasty. Of these, 107 completed 24 h observation and standardized 12-month follow-up; 21 were discharged before completing 24 h and had incomplete longitudinal assessments. Clinical and hemodynamic outcomes were assessed in 107 patients. Exploratory comparisons according to dual antiplatelet therapy (DAPT) adherence and smoking status were performed, including a baseline-adjusted analysis of 12-month ankle-brachial index (ABI). Results: In the 107-patient longitudinal cohort, mean age was 67.0 ± 6.9 years, 45.8% had total occlusions, 83.2% had Peripheral Arterial Calcium Scoring System (PACSS) grade 4 calcification, and 21.5% required adjunctive stenting. Final technical success was achieved in all 128 treated patients (128/128, 100%). No clinically evident distal embolization was documented in the 107 patients completing 24-h observation (0/107; upper two-sided 95% exact confidence limit, approximately 3.4%). No complications were documented before discharge among the 21 patients with incomplete 24-h observation. At one year, median ABI increased from 0.59 to 1.20, and mean Rutherford category improved from 4.16 to 1.64. In exploratory multivariable analysis, DAPT adherence was associated with higher 12-month ABI (adjusted β = 0.321; 95% CI, 0.214–0.427), whereas continued smoking was not statistically significant after adjustment (β = −0.065; 95% CI, −0.146 to 0.016). Conclusions: Substantial one-year clinical and hemodynamic improvements were observed in this selected cohort. Incomplete 24-h safety ascertainment in early-discharge patients and the lack of a comparator group preclude conclusions about the comparative safety of omitting embolic protection. Associations with DAPT adherence and smoking are exploratory and do not establish causality or an optimal DAPT duration.
EUVIMED